Literature DB >> 7568624

Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms.

J R Redman1, B Guardiola-Lemaitre, M Brown, P Delagrange, S M Armstrong.   

Abstract

The chronobiotic properties of melatonin are well documented. For example, following an 8-h phase advance of the light-dark cycle daily injections of melatonin administered at the pre-shift dark onset alter the direction of re-entrainment of rat activity rhythms. Using this 8-h phase advance paradigm, the effects of the melatonin agonist S-20098 (1 mg/kg and 3 mg/kg) on the rat circadian system were compared with those of melatonin. S-20098 altered the direction of re-entrainment in the same manner as melatonin. A study using lower doses of S-20098 showed that the effect on direction of re-entrainment was dose-dependent, with 100% of rats responding at a dose of 100 micrograms/kg. S-20098 may, therefore, have therapeutic potential as a chronobiotic in the treatment of circadian disorders in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568624     DOI: 10.1007/BF02245938

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  20 in total

1.  Hypothalamic melatonin receptor sites revealed by autoradiography.

Authors:  J Vanĕcek; A Pavlík; H Illnerová
Journal:  Brain Res       Date:  1987-12-01       Impact factor: 3.252

2.  Reentrainment of rat circadian activity rhythms: effects of melatonin.

Authors:  J R Redman; S M Armstrong
Journal:  J Pineal Res       Date:  1988       Impact factor: 13.007

3.  [Action of caffeine on the spontaneous motility of the mouse].

Authors:  J R Boissier; P Simon
Journal:  Arch Int Pharmacodyn Ther       Date:  1965-11

4.  Free-running activity rhythms in the rat: entrainment by melatonin.

Authors:  J Redman; S Armstrong; K T Ng
Journal:  Science       Date:  1983-03-04       Impact factor: 47.728

5.  Chronobiology of aging: temperature, sleep-wake rhythms and entrainment.

Authors:  E D Weitzman; M L Moline; C A Czeisler; J C Zimmerman
Journal:  Neurobiol Aging       Date:  1982       Impact factor: 4.673

6.  Circadian rhythm abnormalities in totally blind people: incidence and clinical significance.

Authors:  R L Sack; A J Lewy; M L Blood; L D Keith; H Nakagawa
Journal:  J Clin Endocrinol Metab       Date:  1992-07       Impact factor: 5.958

7.  Effect of melatonin on jet lag after long haul flights.

Authors:  K Petrie; J V Conaglen; L Thompson; K Chamberlain
Journal:  BMJ       Date:  1989-03-18

8.  Dose-dependent entrainment of rat circadian rhythms by daily injection of melatonin.

Authors:  V M Cassone; M J Chesworth; S M Armstrong
Journal:  J Biol Rhythms       Date:  1986       Impact factor: 3.182

9.  Effects of melatonin and the melatonin receptor agonist S-20098 on the vigilance states, EEG spectra, and cortical temperature in the rat.

Authors:  I Tobler; K Jaggi; A A Borbély
Journal:  J Pineal Res       Date:  1994-01       Impact factor: 13.007

10.  Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

Authors:  S M Armstrong; O M McNulty; B Guardiola-Lemaitre; J R Redman
Journal:  Pharmacol Biochem Behav       Date:  1993-09       Impact factor: 3.533

View more
  19 in total

1.  The future of antidepressant pharmacotherapy.

Authors:  David Baldwin; Chris Thompson
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

Review 2.  Melatonin and its receptors: a new class of sleep-promoting agents.

Authors:  Karl Doghramji
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

Review 3.  Depression research: where are we now?

Authors:  Saebom Lee; Jaehoon Jeong; Yongdo Kwak; Sang Ki Park
Journal:  Mol Brain       Date:  2010-03-10       Impact factor: 4.041

4.  Agomelatine: The evidence for its place in the treatment of depression.

Authors:  Daniela Eser; Thomas C Baghai; Hans-Jürgen Möller
Journal:  Core Evid       Date:  2010-06-15

5.  Melatonin phase advances circadian rhythm.

Authors:  M E Attenburrow; B A Dowling; P A Sargent; A L Sharpley; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

6.  Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Authors:  Jana Tchekalarova; Lidia Kortenska; Natasha Ivanova; Milena Atanasova; Pencho Marinov
Journal:  Psychopharmacology (Berl)       Date:  2019-11-13       Impact factor: 4.530

7.  Agomelatine: protecting the CNS from the effects of stress.

Authors:  Stefania Maccari; Ferdinando Nicoletti
Journal:  CNS Neurosci Ther       Date:  2011-10       Impact factor: 5.243

Review 8.  Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

Authors:  Christian de Bodinat; Béatrice Guardiola-Lemaitre; Elisabeth Mocaër; Pierre Renard; Carmen Muñoz; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2010-06-25       Impact factor: 84.694

9.  Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

Authors:  Michel Bourin; Elisabeth Mocaër; Roger Porsolt
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

10.  Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.

Authors:  Amandine Descamps; Colette Rousset; Mark J Millan; Mark Millan; Michael Spedding; Philippe Delagrange; Raymond Cespuglio
Journal:  Psychopharmacology (Berl)       Date:  2009-04-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.